Top Story

GIFT-I: '2D' regimen led to high SVR12 rates in genotype 1b

April 27, 2015

VIENNA — Twelve weeks of therapy with ombitasvir/paritaprevir/ritonavir was associated with 12-week sustained virologic response rates greater than 90% in a cohort of individuals with genotype 1b HCV, according to data presented at the 2015 International Liver Congress.

Lino Rodrigues, Jr, MD, of Abbvie in the United States, presented findings for 342 Japanese patients treated with the co-formulated ‘2D’ regimen, which included 25 mg ombitasvir, 150 mg paritaprevir and 100 mg ritonavir (Abbvie) every day for 12 weeks. Eligible participants had genotype 1b HCV with or without cirrhosis and Child-Pugh score 6 or less.

Meeting News Coverage

Transparency key to increasing vaccination rates

April 27, 2015
BETHESDA, Md. — Providing safe immunization programs and reporting them accurately and transparently to the public can be vital to improving vaccination rates…
Health Care Legislative and Regulatory Update

Act III for meaningful use — The EHR incentive program Stage 3 proposed rule

April 27, 2015
CMS issued its Stage 3 Meaningful Use Proposed Rule on March 30 (Proposed Rule). Stage 3 is expected to be the final stage of the Electronic Health Record (EHR)…
Meeting News Coverage

HCV RNA in liver explants does not lead to HCV recurrence post-transplant

April 27, 2015
VIENNA — The presence of hepatitis C virus infection RNA in liver explants did not correlate with a likelihood of hepatitis C recurrence after liver…

NIH launches clinical trial on statin therapy for HIV patients

April 27, 2015
The NIH announced it is launching a clinical study of HIV patients to test the effectiveness of statins in reducing the risk for major cardiovascular events such as…
More News Headlines »
CME
Regimen Selection in HIV

Regimen Selection in HIV: Considering New Options to Optimize Outcomes
Monograph

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than 2 decades into the antiretroviral therapy (ART) era, numerous options are available for HIV treatment. The…
More »
Meeting News Coverage Video
VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

April 24, 2015
BETHESDA, Md. — Richard K. Zimmerman, MD, of the University of Pittsburgh, explains the results of his study…
More »
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
morganatic-roan